ImaginAb Finds $8M For Immunotherapy Imaging

Inglewood-based ImaginAb, which is developing a cell imaging agent used for imaging changes in cell tumors, has raised $8M in a funding round, the firm said on Monday. The funding was led by Adage Capital, and also included the Parker Institute for Cancer Immunotherapy, NVF, Cycad Group, Nextech Invest, and Jim Pallotta of the Raptor Group. The company said the funding will go towards accelerating clinical development of its CD8 ImmunoPET program, which is an imaging agent used to determine changes in CD8+ T cell tumor infiltrates induced by immuno-oncological treatments. ImaginAb's CEo is Martyn Coombs.